http://www.raredr.com/news/fda-approves-mepsevii "'This approval underscores the agency’s commitment to making treatments available to patients with rare diseases,' said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research (CDER)" It's great to see the FDA focussing on exceedingly rare disorders, but where is the commitment from the FDA to approve treatments for common diseases as well? Fewer than 150 patients worldwide (and perhaps fewer than 7 patients in the United States) might benefit from the FDA approval of Mepsevii. What about the 20,000,000 worldwide ME/CFS sufferers still with no approved treatment? Where is the FDA commitment to them (us)? Priorities seem out of balance at the FDA.